Related Experiment Video
Updated: Mar 23, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Healing livers, saving lives: Hepatitis C screening in an era of cure
Courtney M Boucher1, Anne Walsh, Christopher P Forest
1Courtney M. Boucher is a graduate of the primary care PA program at the University of Southern California (USC) in Alhambra, Calif. She practices emergency medicine in Temecula, Calif. Anne Walsh is an instructor of clinical family medicine at USC's Keck School of Medicine and practices family medicine in Newport Beach, Calif. Christopher P. Forest is an assistant professor of clinical family medicine and director of research at USC's primary care PA program in the Keck School of Medicine and practices urgent care and family medicine in Los Angeles, Calif. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Abstract:
Chronic hepatitis C affects more than 3 million people in the United States. In the past, drug therapy with interferon and ribavirin resulted in low overall cure rates and early discontinuation due to adverse reactions. The new direct-acting antivirals offer not only a shorter duration of treatment with fewer adverse reactions, but greatly improved overall cure rates as high as 96%. Updated national screening recommendations (including a one-time screening for patients born between 1945 and 1965), combined with timely referral and treatment, offer a prime opportunity for healthcare providers to improve public health outcomes and reduce healthcare costs.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

